References in periodicals archive ?
Efforts are made to reduce these chemotherapy-induced complications by ensuring age-dependent doses of dactinomycin and cyclophosphamide, especially in patients <36 months of age.
Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.
Toremifene CYP3A4 Active Induction: [up arrow] efficacy Inhibition: [up arrow] risk of adverse effects Glucocorticoids CYP3A4 Inhibitors: CYP3A4 inducer [up arrow] risk corticosteroid -related toxicity Inducers: [down arrow] efficacy Reduces efficacy of CYP3A4 substrates Table IV Anticancer drugs that are p-glycoprotein substrates Clilorambucil Etoposide Cisplatin Methylprednisolone Dactinomycin Mitoxantrone Daunorubicin Paclitaxel Dexamethasone Tamoxifen Docetaxel Vinblastine Doxorubicin Vincristine